Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S).
The beta-diketo acids (DKAs) represent a major advance for anti-HIV-1 integrase drug development. We compared the inhibition of HIV-1 integrase by six DKA derivatives using the wild-type enzyme or the double-mutant F185K/C280S, which has been previously used for crystal structure determinations. With the wild-type enzyme, we found that DKAs could be classified into two groups: those similarly potent in the presence of magnesium and manganese and those potent in manganese and relatively ineffective in the presence of magnesium. Both the aromatic and the carboxylic or tetrazole functions of DKAs determined their metal selectivity. The F185K/C280S enzyme was markedly more active in the presence of manganese than magnesium. The F185K/C280S integrase was also relatively resistant to the same group of DKAs that were potent in the presence of magnesium with the wild-type enzyme. Resistance was caused by a synergistic effect from both the F185K and C280S mutations. Molecular modeling and docking suggested metal-dependent differences for binding of DKAs. Molecular modeling also indicated that the tetrazole or the azido groups of some derivatives could directly chelate magnesium or manganese in the integrase catalytic site. Together, these experiments suggest that DKAs recognize conformational differences between wild-type and the double-mutant HIV-1 integrase, because they chelate the magnesium or manganese in the enzyme active site and compete for DNA binding.
Marchand
Christophe
C
Laboratory of Molecular Pharmacology, Center for Cancer Research, Bldg. 37, Rm. 5068, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255, USA.
Johnson
Allison A
AA
Karki
Rajeshri G
RG
Pais
Godwin C G
GC
Zhang
Xuechun
X
Cowansage
Kiriana
K
Patel
Tapan A
TA
Nicklaus
Marc C
MC
Burke
Terrence R
TR
Pommier
Yves
Y
D000090:Acetoacetates / Q000737:chemistry* / Q000378:metabolism; D019943:Amino Acid Substitution / Q000235:genetics*; D001665:Binding Sites / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D024882:Drug Resistance, Viral; D019427:HIV Integrase / Q000737:chemistry / Q000378:metabolism*; D019428:HIV Integrase Inhibitors / Q000737:chemistry* / Q000378:metabolism; D008274:Magnesium / Q000737:chemistry* / Q000502:physiology; D008345:Manganese / Q000737:chemistry* / Q000502:physiology; D009154:Mutation; D011485:Protein Binding / Q000235:genetics; D012995:Solubility
D000090:Acetoacetates; D019428:HIV Integrase Inhibitors; D008345:Manganese; D019427:HIV Integrase; D008274:Magnesium